{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:52:52Z","timestamp":1769165572125,"version":"3.49.0"},"reference-count":19,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.3960\/jslrt.20030","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T22:07:09Z","timestamp":1599084429000},"page":"174-178","source":"Crossref","is-referenced-by-count":13,"title":["COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma"],"prefix":"10.3960","volume":"60","author":[{"given":"Rika","family":"Hosoba","sequence":"first","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Shiotsuka","sequence":"additional","affiliation":[{"name":"Office of Infection Control and Prevention, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Office of Infection Control and Prevention, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoko","family":"Nakano","sequence":"additional","affiliation":[{"name":"Office of Infection Control and Prevention, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimiko","family":"Muroya","sequence":"additional","affiliation":[{"name":"Office of Infection Control and Prevention, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Okada","sequence":"additional","affiliation":[{"name":"Nursing Office, Ward 11B, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Nursing Office, Ward 18, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanae","family":"Ida","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko Miyagi","family":"Maeshima","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[{"name":"The COVID-19 Treatment Team, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Iwata","sequence":"additional","affiliation":[{"name":"Office of Infection Control and Prevention, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Fauci AS, Lane HC, Redfield RR. Covid-19 - navigating the uncharted. N Engl J Med. 2020; 382: 1268-1269.","DOI":"10.1056\/NEJMe2002387"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Li Q, Guan X, Wu P <i>et al.<\/i> Early transmission dynamics in Wuhan, China, of novel coronavirus\u2013infected pneumonia. N Engl J Med. 2020; 382: 1199-1207.","DOI":"10.1056\/NEJMoa2001316"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Richardson S, Hirsch JS, Narasimhan M <i>et al.<\/i> Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020; 323: 2052-2059.","DOI":"10.1001\/jama.2020.6775"},{"key":"4","unstructured":"4 Center for Disease Control and Prevention. Coronavirus Disease 2019. Groups at Higher Risk for Severe Illness. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/groups-at-higher-risk.html. [Accessed on 30-May-2020]."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Liang W, Guan W, Chen R <i>et al.<\/i> Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21: 335-337.","DOI":"10.1016\/S1470-2045(20)30096-6"},{"key":"6","unstructured":"6 European Society for Medical Oncology. Cancer patient management during the COVID-19 pandemic. ESMO guidelines. https:\/\/www.esmo.org\/guidelines\/cancer-patient-management-during-the-covid-19-pandemic. [Accessed on 24-Apr-2020]."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Kuderer NM, Choueiri TK, Shah DP <i>et al.<\/i> Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020; 395: 1907-1918.","DOI":"10.1016\/S0140-6736(20)31187-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014; 15: e517-e526.","DOI":"10.1016\/S1470-2045(14)70202-5"},{"key":"9","unstructured":"9 Di Giambenedetto S, Ciccullo A, Borghetti A <i>et al.<\/i> Off-label use of tocilizumab in patients with SARS-CoV-2 infection. J Med Virol.; in press."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Roschewski M, Lionakis MS, Sharman JP <i>et al.<\/i> Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020; 5: eabd0110.","DOI":"10.1126\/sciimmunol.abd0110"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Treon SP, Castillo JJ, Skarbnik AP <i>et al.<\/i> The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19\u2013infected patients. Blood. 2020; 135: 1912-1915.","DOI":"10.1182\/blood.2020006288"},{"key":"12","unstructured":"12 AstraZeneca News Release. AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19. https:\/\/www.astrazeneca.com\/content\/astraz\/media-centre\/press-releases\/2020\/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html. [Accessed on 8-Jun-2020]."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad, Ser B, Phys Biol Sci. 2017; 93: 449-463.","DOI":"10.2183\/pjab.93.027"},{"key":"14","unstructured":"14 Pharmaceutical and Medical Device Agency. Japan. Avigan Review Report. https:\/\/www.pmda.go.jp\/files\/000210319.pdf. [Accessed on 24-Apr-2020]."},{"key":"15","unstructured":"15 Favipiravir Observational Study Group. Preliminary report of the favipiravir observational study in Japan. http:\/\/www.kansensho.or.jp\/uploads\/files\/topics\/2019ncov\/covid19_casereport_en_200529.pdf. [Accessed on 8-Jun-2020]."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Hoffmann M, Kleine-Weber H, Schroeder S <i>et al.<\/i> SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181: 271-280.e8.","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Yamamoto M, Matsuyama S, Li X <i>et al.<\/i> Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob Agents Chemother. 2016; 60: 6532-6539.","DOI":"10.1128\/AAC.01043-16"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Cao B, Wang Y, Wen D <i>et al.<\/i> A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020; 382: 1787-1799.","DOI":"10.1056\/NEJMoa2001282"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Huang C, Wang Y, Li X <i>et al.<\/i> Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497-506.","DOI":"10.1016\/S0140-6736(20)30183-5"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/60\/4\/60_20030\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T04:34:37Z","timestamp":1608352477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/60\/4\/60_20030\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.20030","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}